Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prophylactic or therapeutic agent for diseases of posterior segment of eye

A technology for a disease of the posterior segment of the eye and a therapeutic agent, which is applied in the field of preventive or therapeutic agent for the posterior segment of the eye, and can solve problems such as reports on the effect research of the prevention or treatment.

Inactive Publication Date: 2017-02-22
SANTEN PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, there is no reference to 3-amino-2-oxopyrrolidine derivatives, particularly compounds represented by formula (1), their enantiomers or diastereomers, or their pharmaceutically acceptable salts (the present invention) compound) on the prevention or treatment of eye diseases in the report of the report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic or therapeutic agent for diseases of posterior segment of eye
  • Prophylactic or therapeutic agent for diseases of posterior segment of eye
  • Prophylactic or therapeutic agent for diseases of posterior segment of eye

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0118] The results of pharmacological tests and preparation examples are shown below, but these examples are for better understanding of the present invention and do not limit the scope of the present invention.

[0119] [Pharmacological Test 1]

[0120] The usefulness of the present compound was evaluated using a laser-induced rat choroidal angiogenesis model (Invest. Ophthalmol. Vis. Sci., 40(2), 459-466 (1999)).

[0121] (Method for making rat choroidal neovascularization model animal induced by krypton laser)

[0122] Intramuscularly administer a mixture of 5% (W / V) ketamine hydrochloride injection and 2% xylazine hydrochloride injection (7:1) to rats in an amount of 1 mL / kg, anesthetize them under general anesthesia, and inject After dropping 0.5% (W / V) tropicamide-0.5% phenylephrine hydrochloride eye drops to dilate the pupils, photocoagulation was performed using a krypton laser photocoagulation device. Photocoagulation was carried out as follows: at the local part of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a prophylactic or therapeutic agent for diseases of the posterior segment of the eye, which contains, as an active ingredient, a compound represented by formula (1), an enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof (hereinafter referred to as "the present compound").

Description

technical field [0001] The present invention relates to a preventive or therapeutic agent for posterior segment diseases of the eye, which contains 3-amino-2-oxopyrrolidine derivatives, particularly compounds represented by formula (1), its An enantiomer or a diastereomer, or a pharmaceutically acceptable salt thereof (hereinafter, also referred to as "the present compound") is used as an active ingredient. [0002] [chemical formula 1] [0003] Background technique [0004] The so-called posterior segment diseases usually refer to diseases in the vitreous, retina, choroid, sclera or optic nerve, which are closely related to the appearance of new blood vessels. That is, for diseases of the posterior segment of the eye such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, etc., the hyperactivity of neovascularization is the main factor for the formation and progression of the pathology, and it is known tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/517A61K9/06A61K9/08A61K9/16A61K9/20A61K9/48A61K9/70A61K31/519A61K31/53A61P27/02A61P27/06
CPCA61K9/06A61K9/08A61K31/517A61K31/519A61K9/0051A61K9/2018A61P27/00A61P27/06A61P27/02A61K31/53A61K9/0019A61K9/0048A61K9/16A61K9/20A61K9/48A61K9/70A61K49/0008
Inventor 吉田笃史
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com